Catherine Lok
Catherine Lok is an expert in Dermatology at Centre Hospitalier Universitaire Amiens-Picardie (France). Catherine Lok has authored 315 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 1 of them ongoing. SLR score: 953 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Surgery - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 315
Citations
Main journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Management of erythromelalgia: A retrospective multicenter study. PMID 42470997 — sexually transmitted diseases, erythromelalgia, dermatology | Ann Dermatol Venereol | 2026 | 0 |
| A case of diffuse Gougerot and Blum purpuric pigmented dermatosis. PMID 41171796 — skin diseases | Dermatol Online J | 2025 | 0 |
| Chemotherapy-induced leg ulcers: a case series. PMID 40047813 — neoplasms, leg ulcer, ulcer, drug therapy, therapeutics, hydroxyurea, chemotherapy | J Wound Care | 2025 | 0 |
| Agminated junctional eruptive nevi following Langerhans cell histiocytosis. PMID 39823056 — cells, histiocytosis, langerhans-cell, langerhans cells, histiocytosis, nevus, vemurafenib | JAAD Case Rep | 2024 | 0 |
| List of critical drugs in dermatology: results of a Delphi consensus in France. PMID 39499664 — syphilis, pharmaceutical preparations, dermatology | Br J Dermatol | 2024 | 0 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis NCT04789850 — sclerosis, safety, scleroderma, systemic | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map